Literature DB >> 8980403

CAM 17.1--a new diagnostic marker in pancreatic cancer.

F Gansauge1, S Gansauge, N Parker, M I Beger, B Poch, K H Link, F Safi, H G Beger.   

Abstract

CAM 17.1-Ab is a recently described monoclonal antibody that detects a mucus glycoprotein with high specificity for intestinal mucus, particularly in the colon, small intestine, biliary tract and pancreas. We investigated the expression and release of CAM 17.1 in pancreatic carcinoma cell lines and tissue specimens of normal pancreas, chronic pancreatitis and pancreatic cancer. CAM 17.1 was weakly expressed on normal ductal cells and chronic pancreatitis, whereas it was overexpressed in pancreatic cancer. Serum analysis using a new enzyme-linked antibody sandwich assay (CAM 17.1/WGA) of patients with chronic pancreatitis, pancreatic cancer or other gastrointestinal cancer and of healthy blood donors revealed a high sensitivity (67%) and excellent specificity (90%) of CAM 17.1/WGA assay in pancreatic cancer. In comparison with the tumour marker CA19-9, the sensitivity of the CAM 17.1/WGA assay was similar to the sensitivity of CA 19-9 (67% and 76%, P = 0.22), whereas the specificity of CAM 17.1/WGA assay was higher than in CA 19-9 (90% compared with 78% in chronic pancreatitis, P > 0.05).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980403      PMCID: PMC2074816          DOI: 10.1038/bjc.1996.666

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Carcinoembryonic antigen and recurrent colorectal cancer.

Authors:  J Northover
Journal:  Gut       Date:  1986-02       Impact factor: 23.059

2.  Reoperation directed by carcinoembryonic antigen level: the importance of a thorough preoperative evaluation.

Authors:  P J O'Dwyer; C Mojzisik; D P McCabe; W B Farrar; L C Carey; E W Martin
Journal:  Am J Surg       Date:  1988-02       Impact factor: 2.565

3.  Neutral and acidic species of human intestinal mucin. Evidence for different core peptides.

Authors:  A Wesley; M Mantle; D Man; R Qureshi; G Forstner; J Forstner
Journal:  J Biol Chem       Date:  1985-07-05       Impact factor: 5.157

4.  The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients.

Authors:  T Frebourg; E Bercoff; N Manchon; J Senant; J P Basuyau; P Breton; A Janvresse; P Brunelle; J Bourreille
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

5.  Identification and partial characterization of a new pancreatic cancer-related serum glycoprotein by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and lectin blotting.

Authors:  C K Ching; J M Rhodes
Journal:  Gastroenterology       Date:  1988-07       Impact factor: 22.682

6.  The patterns of coexpression of tumor-associated antigens CA 19-9, TAG-72, and DU-PAN-2 in human pancreatic cancer.

Authors:  I Toshkov; M Mogaki; K Kazakoff; P M Pour
Journal:  Int J Pancreatol       Date:  1994-04

7.  Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated alpha-N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen.

Authors:  H K Takahashi; R Metoki; S Hakomori
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

8.  Expression of TAG-72 in normal colon, transitional mucosa, and colon cancer.

Authors:  M Xu; F X Real; S Welt; M H Schüssler; H F Oettgen; L J Old
Journal:  Int J Cancer       Date:  1989-12-15       Impact factor: 7.396

9.  The use of CA-50 radioimmunoassay in differentiating benign and malignant pancreatic disease.

Authors:  N A Habib; M J Hershman; F Haberland; L Papp; C B Wood; R C Williamson
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

10.  Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.

Authors:  C Haglund; P J Roberts; P Kuusela; T M Scheinin; O Mäkelä; H Jalanko
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

View more
  8 in total

1.  Towards immunotherapy of pancreatic cancer.

Authors:  I F McKenzie; V Apostolopoulos
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

2.  The diagnostic dilemmas in discrimination between pancreatic carcinoma and chronic pancreatitis.

Authors:  A Harlozinska-Szmyrka; M Strutynska-Karpinska
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

Review 3.  Pancreatic cancer screening.

Authors:  Eun Ji Shin; Marcia Irene Canto
Journal:  Gastroenterol Clin North Am       Date:  2012-01-05       Impact factor: 3.806

Review 4.  Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.

Authors:  Chakshu Sharma; Karim M Eltawil; Paul D Renfrew; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

Review 5.  Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview.

Authors:  S Bünger; T Laubert; U J Roblick; J K Habermann
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-31       Impact factor: 4.553

Review 6.  The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates.

Authors:  Katherine E Poruk; D Z Gay; K Brown; J D Mulvihill; K M Boucher; C L Scaife; M A Firpo; S J Mulvihill
Journal:  Curr Mol Med       Date:  2013-03       Impact factor: 2.222

7.  Serum tumor markers in pancreatic cancer-recent discoveries.

Authors:  Felix Rückert; Christian Pilarsky; Robert Grützmann
Journal:  Cancers (Basel)       Date:  2010-06-02       Impact factor: 6.639

Review 8.  Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?

Authors:  Robert S O'Neill; Alina Stoita
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.